- Home
- NWAX vs LXEO Comparison
NWAX vs LXEO Comparison
Compare NWAX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NWAX | LXEO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.5M | 418.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NWAX | LXEO |
|---|---|---|
| Price | $10.01 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 61.0K | ★ 820.5K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $2.26 |
| 52 Week High | $10.25 | $10.99 |
Technical Indicators
Market Signals| Indicator | NWAX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 56.63 |
| Support Level | $9.89 | $6.15 |
| Resistance Level | $10.10 | $7.77 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 84.42 | 85.83 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.